Allogene wins FDA RMAT and Fast Track for cema-cel in first-line large B-cell lymphoma

On 29 July 2026, Allogene Therapeutics announced that the US Food and Drug Administration (FDA) has granted both Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations to cemacabtagene ansegedleucel (cema-cel), its allogeneic (off-the-shelf) anti-CD19 CAR-T therapy, for use as first-line consolidation in patients with large B-cell lymphoma (LBCL) at high risk of relapse.

The designations are supported by the ongoing pivotal ALPHA3 trial, which enrols patients who remain in remission following first-line chemoimmunotherapy but test positive for minimal residual disease (MRD) using Natera's CLARITY MRD assay — an approach intended to intercept relapse before it becomes clinically evident. RMAT status affords Allogene closer FDA engagement and eligibility for priority review, while Fast Track is designed to expedite development and review of therapies addressing serious unmet need.

The move positions cema-cel as a potential first allogeneic CAR-T to be deployed pre-emptively in the first-line setting, rather than after relapse.